This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Celvapan

Nanotherapeutics, Inc.

Drug Names(s): H5N1 (Avian Flu) Vaccine, H5N1 Vaccine (BAX), H1N1 Vaccine (BAX)

Description: This vaccine is a vero-cell based candidate H5N1 pandemic influenza vaccine based on the fully inactivated wild-type H5N1 strain A/Vietnam/1203/2004. The Vero cell line was derived from the kidney of a normal, adult, African green monkey, and has the potential to significantly reduce production time compared to traditional vaccine production methods that use embryonated hens' eggs. The vaccine was developed using a whole-virus process.

Deal Structure: In December 2010, Baxter and Takeda announced that the parties have completed a Development, License and Technology Transfer Agreement. Under the terms of the agreement, Takeda and Baxter will bring Vero cell culture-based influenza vaccines to the Japanese market.

Nanotherapeutics and Baxter
In December 2014, Baxter International announced that it has entered into a definitive agreement to sell its proprietary Vero cell technology and related assets, including its production facility in Bohumil, Czech Republic, to Nanotherapeutics. Financial details were not disclosed.

Partners: Takeda Pharmaceutical Company Ltd


Celvapan News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug